Evidence map›Paper›PMID 29089019›Full record

Trial reportParasites & vectors2017

Assessment of the speed of flea kill of lotilaner (Credelio™) throughout the month following oral administration to dogs.

Daniela Cavalleri, Martin Murphy, Wolfgang Seewald, Jason Drake, Steve Nanchen

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Efficacy of lotilaner (CredelioParasites & vectors · 2026
    Article
  10. Article
  11. Article
  12. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment ofHealthcare (Basel, Switzerland) · 2024
    Review
  13. Effectiveness of lotilaner on furuncular myiasis in dogs naturally infested with Dermatobia hominis (Diptera: Cuterebridae).Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Daniela CavalleriElanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Martin MurphyElanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Wolfgang SeewaldElanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Jason DrakeElanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA. drake_jon_j@elanco.com.ORCID http://orcid.org/0000-0001-6203-0852
Steve NanchenElanco Animal Health, Mattenstrasse 24a, 4058, Basel, Switzerland.
Elanco (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLotilaner (Credelio™, Elanco), a novel isoxazoline, is a systemic insecticide and acaricide that is rapidly absorbed following oral administration to dogs and has a half-life of 30 days. As part of a development program, studies were undertaken to investigate lotilaner's initial and sustained efficacy and speed of kill against fleas.

methodsFour studies were conducted to evaluate the onset of lotilaner's speed of flea knockdown at the time of treatment, and to determine the sustained speed of flea kill (SOK) up to 35 days post-treatment. Each study assessed one or two specific time points (4, 6, 8 and 12 h) post-treatment and following weekly re-infestations. In each study, dogs were randomised to a lotilaner or an untreated group based on pre-administration flea counts, and before treatment were infested with adult Ctenocephalides felis. Dogs randomised to a lotilaner group received a single treatment on Day 0, at the minimum recommended dose rate of 20 mg/kg, 30 (± 5) minutes after being fed. Efficacy was calculated using geometric, and arithmetic mean flea counts in treated versus untreated groups.

resultsOn Day 0, lotilaner efficacy was 89.9% at 4 h, 99.2% at 6 h, 99.9% at 8 h, and 100% at 12 h post-treatment. At each weekly assessment, lotilaner efficacy at 4 h remained at > 97%, at 8 h remained at > 99%, and at 12 h remained at 100% through Day 35. Across all studies, there were no treatment-related adverse events.

conclusionLotilaner's rapid flea knockdown immediately following treatment and sustained SOK through 35 days post-treatment offers a new solution for helping to eliminate the health risks that accompany flea infestations on dogs. The consistency of the rapid, sustained flea SOK demonstrated in these studies generates confidence that monthly use of lotilaner in dogs can be valuable in disrupting the flea life cycle in a contaminated environment, and that newly acquired fleas will die quickly, thereby reducing the discomfort of flea bites. The sustained lotilaner SOK also provides confidence that there will be no "end-of-dose" resurgence in flea burdens with the potential accompanying consequence of flares in flea-bite hypersensitivity.

Indexed as

Administration, OralAnimalsCtenocephalidesDog DiseasesDogsFemaleFlea InfestationsInsecticidesMaleTime FactorsInsecticidesCredelio™Ctenocephalides felisDogFleasLotilanerOralSpeed of kill

Identifiers

PMID29089019
PMCPMC5664906
OpenAlexW2765150341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.